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Extended-spectrum -lactamases (ESBLs) are plasmid
encoded enzymes that confer resistance to -lactam anti-
biotics through the hydrolysis of the -lactam ring. ESBLs
are distributed worldwide with an increasing incidence
and prevalence in the Middle East due to the misuse of
antibiotics and lack of coherent antimicrobial surveillance
studies. The aim of study is to analyze molecularly the
antimicrobial resistance mechanisms of 50 Escherichia coli
and Klebsiella pneumoniae isolates from nosocomial infec-
tions in hospitalized patients in Oman. Screening for anti-
microbial resistance (AR) and ESBL production was
carried out with the disk diffusion and E-test methods fol-
lowing CLSI guidelines. ESBL producers were screened for
blaCTX-M, blaSHV, and blaTEM resistance markers via PCR
using gene-specific primers. All amplified PCR fragments
will be sequenced to determine their allelic variants. In
order to demonstrate the overall genotypic variation,
Pulsed-Field Gel Electrophoresis (PFGE) analyses were
done separately among all E. coli and K. pneumoniae iso-
lates. According to the AR analysis, 82% (41/50) of iso-
lates were determined to be ESBL producing bacteria. The
percentages of isolates with genetic markers for blaCTX-M,
blaSHV, and blaTEM were 73%, 24%, and 68%, respectively.
Preliminary PFGE analyses demonstrated high level of
variation among ESBL isolates compared to non-ESBL
producers. Further surveillance studies are needed to
describe better the AR situation in these hospitals in
Oman.
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